| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | RRM1; R1; RIR1; RR1 |
| Entrez GeneID | 6240 |
| WB Predicted band size | Calculated MW: 90 kDa; Observed MW: 90 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human RRM1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于RRM1抗体的代表性文献摘要(信息基于公开研究整理，非真实文献，仅供参考)：
---
1. **文献名称**: *RRM1 expression as a prognostic biomarker in non-small cell lung cancer*
**作者**: Smith J, et al.
**摘要**: 该研究通过免疫组化(使用抗RRM1单克隆抗体)检测非小细胞肺癌(NSCLC)组织中RRM1蛋白表达水平，发现高表达RRM1的患者对吉西他滨化疗敏感性较低，且总生存期较短，提示RRM1可作为化疗耐药性预测标志物。
---
2. **文献名称**: *Validation of RRM1 antibody for Western blot analysis in colorectal cancer*
**作者**: Lee H, et al.
**摘要**: 研究通过Western blot和免疫荧光技术验证了商用RRM1抗体的特异性，发现其在结直肠癌细胞系中能准确识别约90 kDa的目标蛋白条带，并证实RRM1高表达与肿瘤细胞增殖及5-FU耐药性相关。
---
3. **文献名称**: *RRM1 and ERCC1 co-expression in pancreatic cancer: implications for personalized therapy*
**作者**: Garcia R, et al.
**摘要**: 利用RRM1抗体进行组织微阵列分析，揭示了胰腺癌中RRM1与ERCC1蛋白的共表达模式，表明两者联合检测可优化基于铂类/吉西他滨的化疗方案选择，推动个体化治疗策略。
---
**注**：以上为模拟文献摘要，实际研究需通过PubMed、Google Scholar等平台以“RRM1 antibody”、“RRM1 biomarker”等关键词检索真实文献。
The Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) is a key enzyme involved in DNA synthesis and repair, catalyzing the conversion of ribonucleotides to deoxyribonucleotides—a rate-limiting step in maintaining the dNTP pool for genome replication and repair. As a regulatory subunit of the ribonucleotide reductase complex, RRM1 plays a critical role in cell cycle progression and genomic stability. Dysregulation of RRM1 has been linked to cancer progression, chemoresistance, and patient prognosis, making it a potential therapeutic target and biomarker in oncology.
RRM1 antibodies are essential tools for studying its expression, localization, and function in both research and clinical settings. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence to quantify RRM1 levels in tissues or cell lines, particularly in cancers such as lung, pancreatic, and breast carcinomas. Monoclonal antibodies (e.g., clone EPR3955) are commonly employed for their specificity in recognizing human RRM1 epitopes. Clinically, RRM1 expression levels have been correlated with outcomes in chemotherapy; for example, elevated RRM1 in tumors may confer resistance to gemcitabine-based therapies, guiding personalized treatment strategies. Studies also suggest its prognostic value, with high RRM1 expression often associated with poorer survival in certain cancers. Robust validation of RRM1 antibodies ensures accurate detection, supporting their utility in translational research and diagnostic applications.
×
